BioMarin Pharmaceutical

BMRNintermediary

BioMarin Pharmaceutical is a leader in rare-disease therapeutics with a portfolio of enzyme replacement therapies and the breakthrough growth drug Voxzogo for achondroplasia. Its Roctavian gene therapy for hemophilia A represents a one-time curative approach.

⇄ Compare

Produkte & Umsatz

Umsatzanteil nach Produkt

Umsatzaufschlüsselung ($2.8B)

Statische Daten (Echtzeitfinanzen werden geladen…)

Enzyme Replacement Therapies (45%)

Voxzogo (30%)

Roctavian & Other (15%)

Royalties & Collaborations (10%)

Segmentzusammensetzung und Hauptkunden

Produktdetails

Voxzogo (vosoritide)30%

C-type natriuretic peptide analog for achondroplasia in children

Roctavian (AAV gene therapy)10%

Gene therapy for severe hemophilia A

Enzyme Replacement Therapies45%

Naglazyme, Vimizim, and Palynziq for lysosomal storage disorders and PKU

Lieferkettenbeziehungen

Wettbewerber

Regeneron Pharmaceuticals

Rare disease biologics

Auswirkung: Limited overlap in rare disease

Pfizer Inc.

Gene therapy platforms

Auswirkung: Competing in gene therapy

Novo Nordisk

Rare blood disorders

Auswirkung: Competing in hemophilia

Makro- und Marktkontext

제약 / 바이오Sektornachrichten

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Nächste Katalysatoren

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

Aktuelle Nachrichten

Nachrichten laden...

KI-Analyse

Klicken Sie auf "KI-Analyse abrufen" für eine KI-gestützte Lieferkettenanalyse von BioMarin Pharmaceutical.

Unternehmensinformationen

Hauptsitz

San Rafael, California, USA

Gegründet

1997

Mitarbeiter

4,200+

Website

biomarin.com

Sektorübersicht — 제약 / 바이오

Sektornachrichten